Robert Epstein, MD, MS on Chemotherapy-Induced Myelosuppression: Is the Issue the Same? #ASCO2020 #ASCO

Robert Epstein, MD, MS on Chemotherapy-Induced Myelosuppression: Is the Issue the Same? #ASCO2020 #ASCO

User Photo
Cancer-News

3 months
11 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer.

Background/Key Findings:

  • 301 people with cancer (breast cancer = 153, lung cancer = 100, colorectal cancer = 48) who were treated with chemotherapy in the past year and experienced at least one episode of myelosuppression completed an online survey to assess the impact of chemotherapy-induced myelosuppression.
  • Nearly nine in ten (89%) survey participants reported that myelosuppression had a moderate or major impact on their lives (moderate life impact = 49%, major life impact = 40%).
  • Fatigue was the most commonly reported side effect of chemotherapy, experienced by almost three-quarters of survey participants (72%), with more than half (55%) rating it as highly bothersome (9 or 10 on a 1–10 scale of ‘bothersomeness’).

Read here: https://meetinglibrary.asco.org/record/190476/abstract

Up Next Autoplay